Pegylated Liposomal Doxorubicin As a Single Agent or As Combination Therapy with Carboplatin in Patients with Recurrent or Refractory Epithelial Ovarian Cancer

Keng Shen,Beihua Kong,Yunong Gao,Lingying Wu,Ziting Li,Yile Chen,Mengda Li,Yongliang Gao,Ding Ma,Zhilan Peng
DOI: https://doi.org/10.1007/s11805-009-0387-1
2010-01-01
Clinical Oncology and Cancer Research
Abstract:OBJECTIVE Pegylated liposomal doxorubicin (PLD; CAELYX®), a novel formulation of doxorubicin with enhanced therapeutic efficacy and reduced toxicity, has demonstrated improved progression-free survival in recurrent or refractory ovarian cancer. The objective of this open-label, non comparative, observational study was to determine the effi cacy and safety of PLD monotherapy or combination therapy with carboplatin for patients with recurrent or refractory ovarian cancer.METHODS Sixty-two patients with recurrent or refractory ovarian cancer who completed a platinum-based chemotherapy regimen and demonstrated platinum sensitivity for first-line treatment at least 6 months prior to study entry were enrolled in 20 centers in China. PLD was given as monotherapy (50 mg/m2 infused over 60 minutes) or as combination therapy (30 mg/m21-hour infusion) with carboplatin (area under the curve 5 mg·min/mL 1-hour infusion) on day 1 every 28 days for 4 cycles. The primary endpoint was objective response (OR) rate or CA-125 level. Secondary endpoints included time to response, time-to-progression, health-related quality of life, and safety. RESULTS Overall, 48% of the 62 evaluable patients achieved a confirmed OR. More patients receiving PLD and carboplatin achieved an OR vs the PLD monotherapy group (63% vs. 37%). The median time to response and disease progression was 58.5 days and 56.0 days, respectively. Overall and drug-related adverse events were reported for 39% and 34%, respectively. The most commonly reported adverse events were stomatitis (22.6%) and palmar-plantar erythroderma (9.7%). Two deaths were reported.CONCLUSION PLD is an e ff ective and well tolerated agent in women with recurrent or refractory epithelial ovarian cancer.
What problem does this paper attempt to address?